Table 1. Patient Characteristics.
| Variable | N (%) |
|---|---|
| Gender | |
| Male | 25 (66%) |
| Female | 13 (34%) |
| Median age at time of metastatic diagnosis (range) | 57.9 years (36.8–71.0 years) |
| Up-front extent of disease | |
| Localized | 16 (42%) |
| Metastatic | 22 (58%) |
| ECOG performance status | |
| 0 | 2 (5%) |
| 1 | 21 (55%) |
| 2 | 15 (40%) |
| 3 | 0 (0%) |
| 4 | 0 (0%) |
| IMDC risk score | |
| Good | 7 (18%) |
| Intermediate | 20 (56%) |
| Poor | 9 (26%) |
| Histology | |
| Clear cell | 38 (100%) |
| Sarcomatoid dedifferentiation | 4 (11%) |
| Nephrectomy status | |
| Status post nephrectomy | 32 (84%) |
| Primary in situ | 6 (16%) |
| High-risk sites of metastatic disease | |
| Bone metastasis | 22 (63%) |
| Brain metastasis | 6 (17%) |
| Liver metastasis | 9 (24%) |
| Line of systemic therapy | |
| Second line | 6 (16%) |
| Third line | 10 (26%) |
| Fourth line or later | 22 (58%) |
| Previous TKI | |
| Yes | 38 (100%) |
| No | 0 (0%) |
| Previous immune checkpoint inhibitor | |
| Yes | 24 (63%) |
| No | 14 (37%) |
Note. ECOG = Eastern Cooperative Oncology Group; IMDC = International Metastatic RCC Database Consortium; TKI = tyrosine kinase inhibitor.